Details for Patent: 11,400,087
✉ Email this page to a colleague
Which drugs does patent 11,400,087 protect, and when does it expire?
Patent 11,400,087 protects ABILIFY MAINTENA KIT and is included in one NDA.
Summary for Patent: 11,400,087
| Title: | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
| Abstract: | The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both. |
| Inventor(s): | Raoufinia; Arash (Vienna, VA) |
| Assignee: | Otsuka Pharmaceutical Co., Ltd. (Rockville, MD) |
| Application Number: | 17/304,606 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 11,400,087
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Otsuka Pharm Co Ltd | ABILIFY MAINTENA KIT | aripiprazole | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 202971-001 | Feb 28, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER | ⤷ Sign Up | ||||
| Otsuka Pharm Co Ltd | ABILIFY MAINTENA KIT | aripiprazole | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 202971-001 | Feb 28, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF SCHIZOPHRENIA | ⤷ Sign Up | ||||
| Otsuka Pharm Co Ltd | ABILIFY MAINTENA KIT | aripiprazole | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 202971-001 | Feb 28, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
